XML 15 R6.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (28,212,000) $ (23,623,000)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation expense 582,000 529,000
Amortization of intangible assets 2,371,000 59,000
Amortization of right-of-use assets and liabilities 169,000 959,000
Impairment charge for long-lived assets 88,000
Pro rata loss from equity method investment in Razor 270,000 1,112,000
Stock-based compensation 5,136,000 4,081,000
Unrealized (gain) loss on marketable equity securities (248,000) 18,000
Amortization of debt issuance costs 46,000 80,000
Change in fair value of contingent consideration 2,260,000 (2,980,000)
Deferred income tax benefit (9,358,000) (1,095,000)
Gain on extinguishment of debt (PPP loan) (1,141,000)
Changes in operating assets and liabilities:    
Accounts receivable (824,000) (372,000)
Amount due to Lineage and affiliates (6,000)
Prepaid expenses and other assets (787,000) (529,000)
Accounts payable and accrued liabilities (1,592,000) 1,843,000
Accrued severance from Chronix Biomedical acquisition 2,452,000
Net cash used in operating activities (28,876,000) (19,836,000)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Acquisition of Insight Genetics, net of cash acquired (607,000) (6,189,000)
Acquisition of Razor Genomics asset, net of cash acquired (6,648,000)
Acquisition of Chronix Biomedical, net of cash acquired (4,459,000)
Equity method investment in Razor (4,000,000)
Construction in progress and purchases of furniture and equipment (1,846,000) (1,061,000)
Net cash used in investing activities (13,560,000) (11,250,000)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from exercise of stock options 2,573,000 72,000
Proceeds from sale of common shares 65,262,000 18,343,000
Financing costs to issue common shares (2,676,000) (58,000)
Proceeds from sale of common shares under at-the-market transactions 12,724,000
Financing costs for at-the-market sales (390,000)
Proceeds from exercise of warrants 2,631,000
Common shares received and retired for employee taxes paid (239,000) (14,000)
Repayment of loan payable (1,125,000) (125,000)
Repayment of financing lease obligations (127,000) (53,000)
Proceeds from PPP loan 1,141,000
Net cash provided by financing activities 78,633,000 19,306,000
NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH 36,197,000 (11,780,000)
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING 8,843,000 23,772,000
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING 45,040,000 11,992,000
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION    
Cash paid for interest 96,000 131,000
SUPPLEMENTAL SCHEDULE OF NONCASH FINANCING AND INVESTING ACTIVITIES    
Common stock issued for acquisition of Razor Genomics asset 5,756,000
Deferred tax liability generated from the acquisition of Razor Genomics asset 7,564,000
Common stock issued for acquisition of Insight Genetics 5,000,000
Common stock issued for acquisition of Chronix Biomedical 3,299,000
Deferred tax liability generated from the acquisition of Chronix 1,794,000
Initial fair value of contingent consideration at acquisition date 42,295,000 11,130,000
Assumed liability from Chronix Acquisition 3,489,000
Holdback liability 600,000
Construction in progress, machinery and equipment purchases included in accounts payable, accrued liabilities and landlord liability $ 193,000 $ 1,109,000